Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.42 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 13/20 | 0.38 |
| ▸ | ITK | Q08881 | 3/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | TXK | P42681 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | INSR | P06213 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26584987 | 0.95 | ALK (0.39) | IRAK4MAP3K7IRAK1ALKITK | |
| SCHEMBL26585002 | 0.91 | EGFR (0.46) | IRAK4MAP3K7IRAK1ALKMET | |
| SCHEMBL30528196 | 0.90 | ALK (0.38) | IRAK4MAP3K7IRAK1ALKITK | |
| SCHEMBL26584985 | 0.89 | ITK (0.38) | IRAK4MAP3K7IRAK1ITKTXK | |
| SCHEMBL26584998 | 0.73 | EGFR (0.49) | IRAK4MAP3K7IRAK1ALKMET | |
| SCHEMBL16896194 | 0.71 | EGFR (0.64) | IRAK4MAP3K7IRAK1ITK | |
| SCHEMBL16896195 | 0.71 | EGFR (0.64) | IRAK4MAP3K7IRAK1ITK | |
| SCHEMBL16895698 | 0.71 | EGFR (0.49) | ALKITKMET | |
| SCHEMBL16895696 | 0.71 | EGFR (0.49) | ALKITKMET | |
| SCHEMBL26584990 | 0.70 | OPRM1 (0.41) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | IRAK4 2022/4885MAP3K7 161/4885IRAK1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.